Korean J Intern Med.  2022 May;37(3):653-659. 10.3904/kjim.2021.309.

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin

Affiliations
  • 1Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
  • 2Department of Otolaryngology, Ajou University School of Medicine, Suwon, Korea
  • 3Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Korea
  • 4Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Korea

Abstract

Background/Aims
The study investigated the incidence of thromboembolic events (TEE) in head and neck (H&N) cancer patients who received concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed the factors affecting TEE occurrence
Methods
Two hundred and fifty-seven patients who started CCRT with cisplatin for H&N cancer from January 2005 to December 2019 were analyzed.
Results
TEE occurred in five patients, an incidence rate of 1.9%. The 2-, 4-, and 6-month cumulative incidences of TEE were 0.8%, 1.6%, and 1.9%, respectively. Khorana score was the only factor associated with TEE occurrence (p = 0.010).
Conclusions
The incidence of TEE in H&N cancer patients who underwent CCRT with cisplatin was relatively low when compared to other types of cancer. However, patients with a high Khorana score require more careful surveillance for possible TEE occurrence.

Keyword

Head and neck neoplasms; Cisplatin; Chemoradiotherapy; Khorana score
Full Text Links
  • KJIM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr